Drug intelligence / Profile preview

unrelated umbilical cord blood microtransplantation + venetoclax + decitabine or azacitidine

Development stage: Unknown
Lead developer: The First Affiliated Hospital of USTC
Modality: Small Molecules, Stem Cell Therapies → Cell Therapies
Administration: Intravenous, Oral

Overview

This is a cell-based therapeutic intervention being studied by Anhui Provincial Hospital for the treatment of higher-risk myelodysplastic syndromes (MDS). The treatment involves unrelated umbilical cord blood microtransplantation (UCBM) combined with chemotherapy agents, specifically venetoclax plus either decitabine or azacitidine. The cellular component consists of hematopoietic stem cells and other immune cells from unrelated donor umbilical cord blood, which are used to reconstitute the patient's hematopoietic system. Venetoclax is a BCL-2 inhibitor, while decitabine and azacitidine are hypomethylating agents. This combination aims to improve outcomes in MDS patients by combining the graft-versus-leukemia effect of the cord blood with the anti-leukemic activity of the chemotherapy.

Other names: Unrelated Umbilical Cord Blood MicrotransplantationUCBM

Targets

BCL-2 (BCL-2 family)DNMT1 (DNA (cytosine-5)-methyltransferase 1)

Beyond the preview

Go deeper on unrelated umbilical cord blood microtransplantation + venetoclax + decitabine or azacitidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on unrelated umbilical cord blood microtransplantation + venetoclax + decitabine or azacitidine.

Explore the full profile